Evidence map›Paper›PMID 35224759›Full record

ArticleJournal of cutaneous pathology2022

High cutaneous amphiregulin expression predicts fatal acute graft-versus-host disease.

Brittney Schultz, Daniel D Miller, Todd DeFor, Bruce R Blazar, Angela Panoskaltsis-Mortari, Brian C Betts, Margaret L MacMillan, Daniel J Weisdorf, Shernan G Holtan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cutaneous pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Brittney SchultzDepartment of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-5080-892X
Daniel D MillerDepartment of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA.
Todd DeForHematology and Transplant, University of Minnesota, Minneapolis, Minnesota, USA.
Bruce R BlazarHematology and Transplant, University of Minnesota, Minneapolis, Minnesota, USA.
Angela Panoskaltsis-MortariHematology and Transplant, University of Minnesota, Minneapolis, Minnesota, USA.
Brian C BettsHematology and Transplant, University of Minnesota, Minneapolis, Minnesota, USA.
Margaret L MacMillanHematology and Transplant, University of Minnesota, Minneapolis, Minnesota, USA.
Daniel J WeisdorfHematology and Transplant, University of Minnesota, Minneapolis, Minnesota, USA.
Shernan G HoltanHematology and Transplant, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory DiseaseR01HL155114 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, NOELLE, RANDOLPH J. · 2021 to 2024
$2.7M
NCI NIH HHS P30 CA077598NHLBI NIH HHS R01 HL147324NHLBI NIH HHS R01 HL155114NIAID NIH HHS P01 AI056299NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

backgroundAmphiregulin (AREG) is increased in circulation in acute graft-versus-host disease (aGVHD) and is associated with poor steroid response and lower survival. The expression of AREG in aGVHD target organs and its association with clinical outcomes are unknown.

methodsWe performed AREG immunohistochemical staining on skin specimens from 67 patients with aGVHD between the years 2010 and 2015. Two blinded reviewers assessed AREG expression and scored specimens with a semiquantitative scale ranging from 0 (absent) to 4 (most intense).

resultsMedian AREG score of aGVHD cases was 3. Sixteen of 67 (23.9%) aGVHD cases had an AREG >3. High skin AREG expression (>3 vs. ≤3) was associated with increased overall clinical grade of aGVHD (52.9% vs. 33.4% clinical grade III-IV, p = 0.02), reduced 3-year overall survival (OS; 13% vs. 61%, p < 0.01), and increased 3-year non-relapse mortality (NRM; 56% vs. 20%, p = 0.05).

conclusionHigh skin AREG immunohistochemical expression is associated with high clinical grade aGVHD, poor OS, and increased NRM.

Indexed as

AmphiregulinGraft vs Host DiseaseHematopoietic Stem Cell TransplantationSkinAcute DiseaseHumansNeoplasm Recurrence, LocalSteroidsAmphiregulinAREG protein, humanSteroidsacute GVHDallogeneic hematopoietic cell transplantationamphiregulinepidermal growth factor

Identifiers

PMID35224759
PMCPMC9311189
OpenAlexW4214719218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.